IMVT Immunovant, Inc. Insider Trading

Immunovant COO Melanie Gloria sells 17,714 shares in 2 transactions for $678,604.34 at $38.31 average

Melanie Gloria, Chief Operating Officer of Immunovant, Inc., executed two separate sales on 2026-06-26 totaling 17,714 shares for $678,604.34, reducing her post-transaction holdings to 224,393 shares (a net reduction of 7.3% from pre-transaction levels of 242,107 shares). The blended average sale price of $38.31 sits near the current price of $38.85 and within 1.1% of the 52-week high of $39.28, suggesting the sales occurred at elevated levels relative to the stock's recent trading range. The company reported a full-year net loss of $110,635,000.00 and maintains a negative net income position, which provides material context for executive equity disposition activity at a profitable stock price. The reduction in holdings during a period of significant recent upside (30-day change of +16.3% and 90-day change of +62.0%) is the pattern requiring investor awareness in light of the company's unprofitability.

CTO Jay S Stout sold 40,000 shares (40.0K shares) at blended avg $38.31 for $1,532,309.48 (reducing stake by 15.9%)

Chief Technology Officer Jay S Stout executed 2 separate sales totaling 40,000 shares for $1,532,309.48 on 2026-06-26, reducing his post-transaction holdings to 211,685 shares from a prior 251,685 shares. The transaction occurred near the 52-week high of $39.28 and well into a strong run: the stock has gained 62.0% over the past 90 days and 16.3% over the past 30 days. The company remains deeply unprofitable with a net loss of $110,635,000.00 over its most recent full fiscal year, yet maintains an $8.0B market cap. A 15.9% reduction in one of the CTO's major holdings—a substantial absolute reduction of 40,000 shares—warrants attention in the context of fundamental weakness.

Chief Legal Officer Van sold 17,824 shares (17.8K) for $682,886.90 in two transactions at $38.19 and $38.96 on 2026-06-26.

Tuyl Christopher Van, Chief Legal Officer, executed 2 separate sales totaling 17,824 shares for $682,886.90, reducing non-derivative holdings by 9.0% to 180,597 shares. The blended sale price of $38.31 is close to the current market price of $38.85 and near the 52-week high of $39.28. While the stock has appreciated substantially over the past 30 days (+16.3%) and 90 days (+62.0%), the company remains unprofitable with a net loss of $-110,635,000.00 for the full fiscal year. Van maintains 53,707 shares of stock option holdings, so his overall position has not been fully liquidated. The sale occurred during a period of strong stock momentum and relatively elevated valuation near the 52-week range.

Director Fromkin sold 221,951 shares (222.0K) for $7,438,111.20 in 2 transactions on 5/28, cutting holdings 74.9%

Andrew J. Fromkin, a Director at Immunovant, executed 2 separate sales on 2026-05-28, totaling 221,951 shares for $7,438,111.20 at a blended average price of $33.51. This transaction reduced his direct holdings from 296,333 shares to 74,382 shares, representing a 74.9% reduction in his non-derivative position. The company reported net income of $-110,635,000.00 for its most recent fiscal year and carries a market cap of $6,834,733,846.93. The stock is currently trading at $33.29, up 23.5% over 30 days and 20.0% over 90 days, though it remains 8.2% below its 52-week high of $36.28. The substantial scale of this divestiture—involving over $7.4M in proceeds—reflects a material reduction in the director's direct equity stake at an unprofitable company during a period of positive momentum in the stock price.

Roivant Sciences director bought 16,666,666 IMVT shares at $21.00 ($350.0M); holdings now 113.32M shares (+17.2%)

A Roivant Sciences director made a substantial $350.0M open-market purchase of 16,666,666 shares at $21.00, expanding holdings by 17.2% to 113.32M shares. The transaction occurred at a 20.5% discount to the current price of $26.42, and the stock has appreciated 63.5% over the past 90 days. However, the insider's cross-ticker track record shows only 50% win rate on prior buys with a -7.9% average 90-day return, and at IMVT specifically, two prior buys on 2025-01-13 and 2023-10-02 produced mixed results: the more recent purchase is down 26.6% at the 90-day mark. IMVT remains unprofitable with net income of $-126,502,000.00 over its most recent fiscal year, and the timing of this outsized accumulation after recent sharp gains warrants scrutiny of whether this reflects conviction or represents a post-run-up acquisition by an affiliated party.

Roivant Sciences director buys 16,845,010 IMVT shares at $20.00 for $336,900,200; holdings surge to 96,650,341 shares (+21.1%)

A Roivant Sciences Ltd. director acquired 16,845,010 shares of Immunovant at $20.00 on 2025-01-13, increasing holdings by 21.1% to 96,650,341 shares total. The transaction represents a $336,900,200 commitment at a price $4.40 below the current market level of $24.40. The director's prior buy at this same ticker on 2023-10-02 achieved a 90-day return of +10.9%, establishing a pattern of well-timed accumulation at Immunovant. However, the company remains unprofitable with a net income of $-109,119,000 over its most recent full fiscal year, and the current share price sits 43.1% below the 52-week high, reflecting significant recent weakness.